Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash from Financing Activities: 2022-2024

Historic Cash from Financing Activities for Lexeo Therapeutics (LXEO) over the last 3 years, with Dec 2024 value amounting to $88.8 million.

  • Lexeo Therapeutics' Cash from Financing Activities rose 123644.44% to $100.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $103.8 million, marking a year-over-year change of. This contributed to the annual value of $88.8 million for FY2024, which is 14.47% down from last year.
  • Latest data reveals that Lexeo Therapeutics reported Cash from Financing Activities of $88.8 million as of FY2024, which was down 14.47% from $103.8 million recorded in FY2023.
  • Lexeo Therapeutics' 5-year Cash from Financing Activities high stood at $103.8 million for FY2023, and its period low was $189,000 during FY2022.
  • In the last 3 years, Lexeo Therapeutics' Cash from Financing Activities had a median value of $88.8 million in 2024 and averaged $64.3 million.
  • As far as peak fluctuations go, Lexeo Therapeutics' Cash from Financing Activities surged by 54,815.87% in 2023, and later decreased by 14.47% in 2024.
  • Lexeo Therapeutics' Cash from Financing Activities (Yearly) stood at $189,000 in 2022, then surged by 54,815.87% to $103.8 million in 2023, then decreased by 14.47% to $88.8 million in 2024.